Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT

Status Recruiting

Clinical Trial Summary

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease and inflammatory bowel disease. Some researches identified FAP expression in synovial samples taken from both rheumatoid arthritis and osteoarthritis patients.Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of arthritis than 18F-FDG PET/CT.

Clinical Trial Description

Arthritis is a term used to mean any disorder that affects the joints. The two most common forms of arthritis are osteoarthritis and rheumatoid arthritis.Rheumatoid arthritis is an autoimmune chronic inflammatory disease of unknown etiology and is characterized by chronic inflammation of the joint capsule's synovial membrane. This chronic inflammation ultimately destroys the underlying cartilage and bone. Activated fibroblast-like synoviocytes (FLS) line the synovial membrane and are a prominent cell type responsible for inflammation and joint destruction. Osteoarthritis is characterized by degradation of joint cartilage. Studies demonstrate chondrocytes expressed FAP and that chondrocyte FAP expression was elevated in patients with osteoarthritis. Other researches identified FAP expression in synovial samples taken from both rheumatoid arthritis and osteoarthritis patients. However, FAP expression was greater in samples taken from refractory rheumatoid arthritis patients in comparison to end-stage osteoarthritis patients.68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease and inflammatory bowel disease. Recently the investigators have published an article of the application of 68Ga-FAPI in IgG4-related disease which showed it was more sensitive than FDG in detecting a certain type of inflammations. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of arthritis than 18F-FDG PET/CT. ;

Study Design

Related Conditions & MeSH terms

Arthritis

Clinical Trial Details

NCT number	NCT04514614
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Yaping Luo, MD
Phone	86-10-69155513
Email	luoyaping@live.com
Status	Recruiting
Phase	Early Phase 1
Start date	September 1, 2020
Completion date	December 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04228458` - ThermRheum Version 1	N/A
Withdrawn	`NCT04976972` - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation	N/A
Completed	`NCT04037436` - Functional Exercise and Nutrition Education Program for Older Adults	N/A
Completed	`NCT00069342` - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed	`NCT02944448` - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee	Phase 2
Recruiting	`NCT02498808` - Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?	N/A
Recruiting	`NCT02777060` - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures	N/A
Enrolling by invitation	`NCT02487888` - A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care	N/A
Withdrawn	`NCT02136251` - Total Shoulder Replacement Outcomes With Autologous Bone Graft as Fixator for Glenoid Anchor Peg.
Completed	`NCT02143206` - Modifying Exercise for the COPD Patient
Completed	`NCT01407874` - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2
Completed	`NCT01285843` - Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component	N/A
Completed	`NCT00987870` - Safety and Efficacy of BFH772 in Psoriasis Patients	Phase 1/Phase 2
Completed	`NCT01172327` - Self-Directed Exercise Program for Adults With Arthritis	N/A
Completed	`NCT01184924` - Evaluation of the Arthritis Foundation Tai Chi Program	N/A
Completed	`NCT00750984` - A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing	N/A
Active, not recruiting	`NCT00611585` - A Safety and Efficacy Study of the Birmingham Hip Resurfacing System	N/A
Completed	`NCT00379184` - Sensitization in Osteoarthritic Knees	N/A
Completed	`NCT00403676` - Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease	N/A
Completed	`NCT00175448` - Comparison of Physiotherapy Versus Home Exercise Following Hip Replacement Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.